“…However, disadvantages of these models include off‐target effects in tissues other than the tissue of interest high development cost and time. Biomaterial scaffolds have been used to recruit tumor cells in models of breast (Aguado et al, ; Aguado et al, ; Aguado et al, ; Azarin et al, ; Carpenter, Kwak, Peyton, & Lee, ; Rao et al, ; Seib, Berry, Shiozawa, Taichman, & Kaplan, ), prostate (Bersani et al, ), ovarian (de la Fuente et al, ), melanoma (Ko et al, ), and leukemic (J. Lee et al, ) cancers. The abundance of tumor cells at a site that is readily modifiable provides a platform for probing the premetastatic and metastatic niche; however, to this point, only individual factors have been identified for their ability to enhance tumor cell abundance (Aguado et al, ; Aguado et al, ; Azarin et al, ), yet no alterations have been found that reduce tumor cell abundance relative to control, nor has the interplay between the immune microenvironment present in a scaffold and the subsequent abundance of tumor cells been fully investigated.…”